Search clinical trials for: Staphylococcal investigational vaccine GSK2392105A

Total 104 results

Meissa Vaccines, Inc.

Recruiting

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

Covid19

United States
Pfizer

Completed

SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults

Staphylococcal Infections

Japan
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
GlaxoSmithKline

Completed

A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

United States, Canada, Sweden
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)

Influenza

Japan
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years

Clostridium Infections

Belgium
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Respiratory Syncytial Virus Infections

Argentina, United States, Germany, Spain, Poland, Canada, Japan, Netherlands
GlaxoSmithKline

Completed

Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

Respiratory Syncytial Virus Infections

United States, Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People

Influenza

Germany, Sweden, Netherlands
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults

Influenza

France
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older

Influenza

United States, Canada
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

Panama, New Zealand, South Africa
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children

Influenza

Australia, Singapore
GlaxoSmithKline
Aeras

Completed

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents

Tuberculosis

South Africa
GlaxoSmithKline

Active, not recruiting

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

Respiratory Syncytial Virus Infections

Spain, United States, Belgium, Poland
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Children

Influenza

United States
GlaxoSmithKline

Completed

Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children

Influenza

United States
GlaxoSmithKline

Completed

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

Infections, Papillomavirus | Papillomavirus Vaccines

Belgium, United States
GlaxoSmithKline

Withdrawn

Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults

Influenza
BioNTech SE
Pfizer

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

COVID-19 | Influenza

United States
GlaxoSmithKline

Completed

A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine

Respiratory Disorders

Germany, Canada, United Kingdom
GlaxoSmithKline

Completed

A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.

Respiratory Disorders

France, Germany, Spain, United States, Belgium, Italy, Canada, United Kingdom
GlaxoSmithKline

Completed

A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults

Respiratory Disorders

Belgium
Sinovac Life Sciences Co., Ltd.

Recruiting

Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Pneumococcal Infections

China
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

Influenza

United States
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Completed

An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization

Varicella

China
GlaxoSmithKline
Aeras

Completed

Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342

Tuberculosis

Belgium
GlaxoSmithKline

Completed

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Infections, Papillomavirus

United States, Spain, Finland, Germany, Taiwan, Belgium, Philippines, Canada, Australia, United Kingdom, Thailand, Brazil, Italy, Mexico
ModernaTX, Inc.

Completed

A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults

SARS-CoV-2

Australia
GlaxoSmithKline

Terminated

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease

Tuberculosis

Taiwan, Estonia
Bill & Melinda Gates Medical Research Institute
Bill and Melinda Gates Foundation; Wellcome Trust

Recruiting

Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults

Tuberculosis

Indonesia, Kenya, South Africa, Vietnam, Malawi, Mozambique, Zambia
GlaxoSmithKline

Completed

Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.

Prophylactic Pneumococcal Diseases

Belgium
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children

Malaria

Kenya
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response to an Investigational Dengue Type 2 Vaccine

Dengue Virus

United States
GlaxoSmithKline

Completed

Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)

Influenza

Germany
Merck Sharp & Dohme LLC

Completed

A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)

Healthy | Pneumococcal Infections
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants

Malaria

Malawi
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children

Influenza

United States, Germany, Poland, Spain, Czechia, Bangladesh, France
GlaxoSmithKline

Completed

Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM

Measles | Rubella | Mumps | Varicella

India
GlaxoSmithKline

Completed

Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine

Respiratory Disorders

France, Estonia, Spain, Finland, Italy
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults

Tuberculosis

India
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Enrolling by invitation

An Immunity Persistence Study of Live Attenuated Varicella Vaccine

Varicella

China
Matrivax Research and Development Corporation

Completed

Safety and Immunogenicity of Typhax, a Typhoid Vaccine

Typhoid Fever
GlaxoSmithKline
Aeras

Completed

Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults

Tuberculosis | Tuberculosis Vaccines

South Africa, Kenya, Zambia
GlaxoSmithKline

Completed

Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine

Infections, Meningococcal

Germany
Vaximm GmbH
Pfizer; Merck KGaA, Darmstadt, Germany

Active, not recruiting

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

Recurrent Glioblastoma

Germany
GlaxoSmithKline

Terminated

Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

Influenza

Norway
GlaxoSmithKline
Aeras

Completed

Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants

Tuberculosis

Gambia
GlaxoSmithKline

Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds

Infections, Meningococcal

Thailand, Panama, Philippines
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children

Virus Diseases

Mali, Senegal

3

Subscribe